

AGREEMENT WITH PATIENT ASSOCIATION Project support

This Agreement is made by and between

JANSSEN-CILAG A/S, a Johnson & Johnson company with its registered address at Østbanegade 123, DK-2100 Copenhagen, Denmark, VAT no.: DK19248615

hereinafter “**Company**”;

and

PATIENTFORENINGEN LUNGEKRÆFT, Nørretorv 30 2., 4100 Ringsted, Denmark, CVR: 33848072

hereafter referred to as “**Organization**”

Company and Organization are individually referred to as a “**Party**”, collectively referred to as the “**Parties**”.

WHEREAS:

- Company is a research-oriented pharmaceutical company active in the development and marketing of medicinal products
- Organization is a patient organization; Patientforeningen Lungekræft is a nationwide independent association for Danes with lung cancer or mesothelioma and their relatives. The association was founded in 2005;
- Organization has asked Company to support one of its projects and Company has agreed to provide support under the terms of this agreement.

THE PARTIES TO THIS AGREEMENT AGREE AS FOLLOWS:

Article 1: Scope

1. Organization will carry out the Project for which Company will provide support and Organization shall ensure that the contribution is used in a professional and ethical

manner consistent with this Agreement and applicable rules, legislation and code of practice. More details on the Project (including the objective, roles and responsibilities of both parties, contact persons, outputs, reporting and timelines) are included in **Annex 1**,

2. Organization will use the support provided by Company exclusively for the purpose of the Project.

Article 2: Support

1. The total amount of support that Company will provide for the Project amounts to **30,000.00 DKK**.
2. Further details on the level and type of support, including payment method and timelines, are included in **Annex 1**.
3. Organization and Company acknowledge and agree that the support shall not obligate Organization to purchase, use, recommend, or arrange for the use of any products of Company.
4. EU and National legislation and codes of practice prohibiting the advertising of prescription-only medicines to the general public, apply. Organization and Company acknowledge and agree that Company shall not request, nor shall Organization undertake, the promotion of a particular prescription-only medicine.
5. Organization represents and warrants that it is a tax-exempt entity under the applicable laws and that it is authorized to accept support in the form of financial contribution or other support from private companies such as Company, and that, to the extent applicable, it has performed the necessary notifications or received the necessary approvals. Organization will also keep Company regularly informed of its direct or indirect relationships with government officials and/or government authorities.
6. If any funds provided by Company to Organization under this Agreement remain upon completion of the Project, such surplus shall be refunded by Organization to Company within forty-five (45) days of completion of the project.

Article 4: Transparency

1. In order to create appropriate transparency on the support to patient organizations by Company, and in line with the applicable code(s) of practice, Company will make

the existence of this agreement and details relating thereto publicly available at Janssen Denmark Website www.janssen.com/denmark and Organization explicitly agrees with such disclosure. More precisely, Company will make the following details publicly available:

- a) Date that the contract was executed;
- b) Name of the patient organization;
- c) Country of the patient organization;
- d) Web address of the patient organization, if available;
- e) Description of the nature and the purpose of the contribution;
- f) Amount as contracted, if financial.

In addition, Company will also make copies of this contract available to interested parties upon their request.

2. Company is entitled to increase the level of details made publicly available to patient organizations either as required by applicable rules and legislation, or upon notice to Organization.
3. This article shall survive any termination of the Agreement.

Article 5: Term and termination

1. This Agreement will take effect on the date when the last of the parties has signed, hereafter the Effective Date, and will remain in effect up until the completion of the Project
2. Both parties have the right to terminate this Agreement upon 2 months written notice notified by registered mail. The respective rights and obligations of both parties in case of early termination of the Project or this Agreement are included in **Annex 1**.

Article 6: Confidentiality

1. During the execution of this Agreement, Organization may have access to certain Confidential Information of Company. Confidential Information shall mean all confidential or proprietary information and materials related to the subject matter of this Agreement and all related trade secrets, know-how, formulations, techniques, methodology equipment, data reports, computer software and information regarding sources of supply, patent positioning, business plans and the existence, scope and activities of any research, developments, manufacturing, marketing or

other projects of Company. Information shall not be considered confidential unless it is reduced to writing and marked "CONFIDENTIAL." An oral disclosure shall only be considered confidential if it is reduced to writing and sent to Organization within 30 (thirty) days after the oral disclosure.

2. Organization shall not make any commercial or other use of the Confidential Information other than for the purpose of this Agreement without the prior written consent of Company. Organization shall disclose or deliver Confidential Information only to persons within its organization who have a need to know for the performance of their duties and who are bound by obligations of secrecy no less strict than those set out herein. Organization shall notify Company promptly of its knowledge of any unauthorized use or disclosure of Confidential Information.
3. Organization shall not disclose, communicate or in any way divulge any Confidential Information to any other person or entity outside its own organization, or permit or suffer its members to do so. Organization shall use the same degree of care, but not less than a reasonable degree of care, to prevent the disclosure of Confidential Information to others as it uses to prevent disclosure of its own confidential or proprietary information.
4. Notwithstanding the provisions of this article, Organization may use or disclose Confidential Information to the extent Organization can demonstrate, by clear and convincing evidence that such Confidential Information:
 - at the time of disclosure to Organization is generally available to the public, or after such disclosure becomes generally available through no wrongful act of Organization,
 - is rightfully in the possession of Organization prior to the time of disclosure,
 - is disclosed by Organization in order to comply with the requirements of applicable law or governmental regulations, provided Organization gives Company prior written notice of such disclosure and takes reasonable actions to avoid such disclosure or minimize its extent,
 - is independently developed by Organization without the aid, application or use of the Confidential Information received from Company.
5. Organization agrees that Company is and shall remain the exclusive owner of the Confidential Information and all patents, copyright, trade secret, trademark, know-how and other intellectual property rights therein. No license or conveyance of any such rights to Organization is granted or implied under this Agreement.
6. Upon termination of this Agreement or at the request of Company, Organization shall promptly deliver to Company all data, memoranda and other tangible manifestations of, and all materials consisting of Confidential Information (and all copies and reproductions thereof).

7. All obligations of confidentiality under this Agreement shall terminate ten (10) years from the date of the end of the Agreement.

Article 7: Right of Use

1. Organization hereby grants Company a non-exclusive worldwide and in time unlimited right to use in all possible forms and media all copyrightable documents or products which are created by Organization in the course of performance of this Agreement (hereinafter the “**Work**”), including, without limitation the right to use, adapt, edit, chose a title for the Work, translate, input and/or combine into (conventional, electronic, digital) database, reproduce (regardless of media of reproduction and of number of reproduced copies), publish, make available online (including in intranets and in the internet), sell, lease, give away for free, exhibit, record, film, and broadcast the Work, in its entirety or in part, in all forms of media, whether in printed or recorded form (analogous or digital), and regardless of whether in writing, as sound and/or as image, and regardless of whether for commercial or charitable purpose (“**Right of Use**”). The remuneration of Organization pursuant to this Agreement shall serve as sufficient consideration for granting of the Right of Use.
2. The Right of Use shall survive the termination of this Agreement. Company shall be entitled to assign or to sublicense in part or in full said Right of Use.
3. Organization warrants that in granting the Right of Use, no rights of third parties, including data privacy rights have been infringed and that where necessary, Organization has obtained approval by third parties in order to grant said Right of Use to Company. Organization shall hold Company harmless against third party claims for infringement of copyrights related to the Right of Use granted to Company and shall assist Company in defending against such third party claims.

Article 8: General Provisions

1. General Anti-Corruption Compliance Provision

Neither party shall perform any actions that are prohibited by local and other anti-corruption laws (collectively “**Anti-Corruption Laws**”) that may be applicable to one or both parties to the Agreement. Without limiting the foregoing, neither party

shall make any payments, or offer or transfer anything of value, to any government official or government employee, to any political party official or candidate for political office or to any other third party related to the transaction in a manner that would violate Anti-Corruption Laws.

2. Personal Data

Company needs to collect personal information from the Organization, and Company and its affiliates will use such information, in order to manage Company's relationship with the Organization pursuant to this letter agreement. A list of affiliates is at <http://www.investor.jnj.com/sec.cfm> (click on the link to Form 10K, Exhibit 21, under "SEC Filings"). Company may also disclose the Organization's personal information to third-party service providers, such as technology and marketing service providers, and parties engaged in the organization of events, including hotels and airlines. If the Organization does not provide the personal information requested, Company will not be able to fulfill its obligations to the Organization pursuant to this letter agreement. Based on the Company's legitimate interests, Company may use the Organization's personal information to compile statistical data based on the information in our databases, as well as on surveys, customer feedback questionnaires, and similar communications.

The Organization may contact Company with questions or request to review the personal information Company has collected and/or to request its correction, deletion, blocking, data portability or restriction at: jacdk@its.jnj.com. The Organization may also lodge a complaint with a data protection authority for the Organization's country or region.

The use and disclosure of personal information may involve a transfer to other jurisdictions, including the U.S., which may provide for different data protection rules than in the Organization's country. Appropriate contractual and other measures are in place to protect personal information when it is transferred. The Organization may obtain a copy of these measures by contacting the Company's data protection officer responsible for the Organization's country or region, if applicable, at emeaprivacy@its.jnj.com.

Company will retain the Organization's personal information for as long as needed or permitted in the light of the purpose(s) for which it was obtained, based on: (i) the length of time Company has an ongoing relationship with the Organization; (ii) whether there is a legal obligation to which Company is subject; and (iii) whether retention is advisable in light of the Company's legal position.

3. Governing Law

This Agreement shall be governed by and construed under the laws of Denmark, without reference to the conflict of law rules.

4. Dispute Resolution

In case of any dispute arising out of or in connection with this Agreement, the Parties shall first attempt (in good faith) to reach an amicable settlement. Should such amicable settlement fail, the courts of Denmark shall have exclusive jurisdiction.

5. Electronic Signatures

The Parties explicitly agree to execute this Agreement by way of an electronic signature, and agree this shall constitute a valid and enforceable agreement between the Parties. The present Agreement is made in an electronic pdf-version (using Adobe Sign) which shall be electronically signed by each Party. Each Party hereby acknowledges receipt of the e-signed agreement, electronically signed for approval by both Parties.

For Company:

Madina Saidj Electronically signed by: Madina Saidj
Reason: I acknowledge that my
electronic approval is legally binding
Date: Jan 27, 2026 13:05:53 GMT+1 Market Access and Public Affairs Leac

For ORGANIZATION:

Lisbeth Søbak Hansen Electronically signed by: Lisbeth Søbak
Hansen
Reason: I acknowledge that my electronic
signature is the legally binding equivalent for
my handwritten signature
Date: Jan 30, 2026 22:53:29 GMT+1 Formand

Annex 1: Project details



Johnson & Johnson
Østbanegade 123
2100 København Ø

D. 9. januar 2026

Ansøgning om støtte til opdatering af hjemmeside og håndbog

Patientforeningen Lungekræft ansøger hermed Johnson & Johnson om

Kr. 30.000,00

opdatering af vores hjemmeside samt håndbog.

I forbindelse med opdateringen ønsker vi at ligge mere at det der skal opdateres jævnlige ind på hjemmesiden og resten skal ind i håndbogen. Med dette tiltag for vi en mere opdateret hjemmeside samt håndbog.

Budget

Opdatering af hjemmeside, kortlægning mv	kr. 93.550,00
Opdatering af "Min egen håndbog" layout, Rentegning, korrektur mv.	kr. 90.400,00
Justering i 2 år	kr. 23.700,00
Tryk af håndbog	kr. 23.000,00
I alt	kr.230.650,00

Patientforeningen Lungekræft
Industrivej 21
4000 Roskilde

Tlf: 4016 2335
info@lungekraeft.com
www.lungekraeft.com



Patientforeningen Lungekræft er en landsdækkende forening for patienter og pårørende med lunge- og lungehindekræft og deres pårørende. Foreningen har eksisteret siden 2005 og ca. 500 medlemmer fra hele landet. Vi som forening arbejder for at forbedre forholdene for lungekræftpacienterne. Læs mere på vores hjemmeside www.lungekraeft.com.

Har I spørgsmål til ovennævnte, er I meget velkommen til at kontakte undertegnede.

Med venlig hilsen

Lisbeth Søbæk Hansen

Formand

Patientforeningen Lungekræft

Patientforeningen Lungekræft
Industrivej 21
4000 Roskilde

Tlf. 4016 2335
info@lungekraeft.com
www.lungekraeft.com

Payment method:

Company shall pay the Support within 45 days of being issued an invoice. Payments shall be made by bank transfer and only to a bank account held in the name of the Party on Invoice. Invoices should, as a minimum requirement, contain the following items: (a) full name and address of Party issuing the invoice; (b) where applicable tax number of Party issuing the invoice; (c) full name and address of the Company or its appointed agent; (d) place and date of invoice; (e) brief description of services invoiced with date of service rendered; and (f) where value added tax (VAT) is applicable, invoicing Party's VAT number, statement of net amounts invoiced, VAT rate, amount and gross amounts. Company will inform the Organization in case the invoice needs to be addressed to its appointed agent instead of to Company.

Reporting:

Within 1 month from the activity, the organization will write a small report as proof of event. The report should consist of:

- A letter on the organization's own letterhead-paper, signed by them, where they explain how the grant/support was used and confirm that the grant/support (amount) has been used as agreed upon.

And at least one of following:

- Final agenda/Advertisement/ Receipts of costs/ detailed financial accounting for use of the support

Those parts can be combined in the same document, but the content must align with the requirements.











[2312140] Sponsorship - Other

Final Audit Report

2026-01-30

Created:	2026-01-27
By:	J&J ICD system (icdsup@its.jnj.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAA3PyBJOhDvAfeGHhVxW9d5Bl4HuX6AlcQ

"[2312140] Sponsorship - Other" History

-  Document created by J&J ICD system (icdsup@its.jnj.com)
2026-01-27 - 11:58:04 AM GMT- IP address: 199.65.21.16
-  Document emailed to info@lungekraeft.com for signature
2026-01-27 - 11:58:52 AM GMT
-  Document emailed to Madina Saidj (msaidj@its.jnj.com) for signature
2026-01-27 - 11:58:53 AM GMT
-  Email viewed by Madina Saidj (msaidj@its.jnj.com)
2026-01-27 - 12:04:42 PM GMT- IP address: 165.225.194.174
-  Madina Saidj (msaidj@its.jnj.com) has agreed to the terms of use and to do business electronically with JOHNSON AND JOHNSON SERVICES, INC.
2026-01-27 - 12:05:53 PM GMT- IP address: 165.225.194.174
-  Document e-signed by Madina Saidj (msaidj@its.jnj.com)
Signing reason: I acknowledge that my electronic approval is legally binding
Signature Date: 2026-01-27 - 12:05:53 PM GMT - Time Source: server- IP address: 165.225.194.174
-  Email viewed by info@lungekraeft.com
2026-01-30 - 9:50:23 PM GMT- IP address: 62.199.46.153
-  Signer info@lungekraeft.com entered name at signing as Lisbeth Søbæk Hansen
2026-01-30 - 9:53:27 PM GMT- IP address: 62.199.46.153
-  Lisbeth Søbæk Hansen (info@lungekraeft.com) has agreed to the terms of use and to do business electronically with JOHNSON AND JOHNSON SERVICES, INC.
2026-01-30 - 9:53:29 PM GMT- IP address: 62.199.46.153
-  Document e-signed by Lisbeth Søbæk Hansen (info@lungekraeft.com)
Signing reason: I acknowledge that my electronic signature is the legally binding equivalent for my handwritten signature
Signature Date: 2026-01-30 - 9:53:29 PM GMT - Time Source: server- IP address: 62.199.46.153

✔ Agreement completed.

2026-01-30 - 9:53:29 PM GMT